Skip to main content

Advertisement

SpringerLink
Log in

Developmental Therapeutics in Acute Myelogenous Leukemia: Are There Any New Effective Cytotoxic Chemotherapeutic Agents Out There?

  • Acute Leukemias (E Feldman, Section Editor)
  • Published:
Current Hematologic Malignancy Reports Aims and scope Submit manuscript

Abstract

Therapies for AML have remained mostly unchanged since the introduction of anthracyline- and cytarabine-based regimens in the 1970s. Though some changes have been made in the dosing of anthracylines, in the choice of consolidation regimens versus allogeneic stem cell transplant, and in supportive care, clinical outcomes remain poor for most patients. As we continue to strive for better treatment options to improve upon outcomes, different agents, both chemotherapeutic and targeted therapies, are being studied. Here we discuss new chemotherapeutic agents that show promise in recent clinical trials and attempt to answer the question if there are any new effective cytotoxic chemotherapy agents out there.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. New Engl J Med. 1999;341:1051–62.

    Article  PubMed  CAS  Google Scholar 

  2. National Cancer Institute: SEER Cancer Statistics Review, 2975–2009. Available at http://seer.cancer.gov/csr/1975_2009pops09/. Accessed December 2012.

  3. Estey EH. Therapeutic options for acute myelogenous leukemia. Cancer. 2001;92:1059–73.

    Article  PubMed  CAS  Google Scholar 

  4. Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. Blood. 2006;107:3481–5.

    Article  PubMed  CAS  Google Scholar 

  5. Estey EH. Acute myeloid leukemia and myelodysplastic syndromes in older patients. J Clin Oncol. 2007;25:1908–15.

    Article  PubMed  Google Scholar 

  6. Breems DA, Van Putten WL, Huijgens PC, et al. Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol. 2005;23:1969–78.

    Article  PubMed  Google Scholar 

  7. Bennet J, Young M, Andersen J, et al. Long-term survival in acute myeloid leukemia: the Eastern Cooperative Oncology Group experience. Cancer. 1997;80:2205–9.

    Article  Google Scholar 

  8. Byrd JC, Mrözek K, Dodge R, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia; results from the Cancer and Leukemia Group B (CALGB 8461). Blood. 2002;100:4325–36.

    Article  PubMed  CAS  Google Scholar 

  9. Yates JW, Wallace Jr HJ, Ellison RR, et al. Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia. Cancer Chemother Rep. 1973;57:485–8.

    PubMed  CAS  Google Scholar 

  10. Fernandez HF, Sun Z, Yao X, et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med. 2009;361:1249–59.

    Article  PubMed  CAS  Google Scholar 

  11. Löwenberg B, Ossenkoppele GJ, van Putten W, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med. 2009;361:1235–48.

    Article  PubMed  Google Scholar 

  12. Döhner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115:453–74.

    Article  PubMed  Google Scholar 

  13. Burnett AK, Russell NH, McMullin MF, et al. A randomised comparison of clofarabine versus low dose Ara-C as first line treatment for older patients with AML. Blood (ASH Ann Meet Abstr). 2012;120:889.

    Google Scholar 

  14. Farderl S, Wetzler M, Rizzieri D, et al. Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I trial. J Clin Oncol. 2012;30:2942–9.

    Google Scholar 

  15. Faderl S, Ravandi F, Huang X, et al. Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients. Cancer. 2012;118:4471–7.

    Article  PubMed  CAS  Google Scholar 

  16. • Nazha A, Ravandi F, Kantarjian HM, et al. Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients < = 60 years with newly diagnosed acute myeloid leukemia (AML). Blood (ASH Ann Meet Abstr). 2012;120:47. Addition of clofarabine to “7 + 3” induction chemotherapy in younger AML patients.

    Google Scholar 

  17. O’Brien S, Rizzieri DA, Vey N, et al. Elacytarabine has single-agent activity in patients with advanced acute myeloid leukaemia. Br J Haematol. 2012;158:581–8.

    Article  PubMed  Google Scholar 

  18. Sandvold ML, Galmarini C, Myhren F, et al. The activity of the lipophilic nucleoside derivatives elacytarabine and CP-4126 in a panel of tumor cell lines resistant to nucleoside analogues. Nucleosides, Nucleotides Nucleic Acids. 2010;29:386–93.

    Article  PubMed  CAS  Google Scholar 

  19. Breistol K, Balzarini J, Sandvold ML, et al. Antitumor activity of P-4055 (elaidic acid-cytarabine) compared to cytarabine in metastatic and s.c. human tumor xenograft models. Cancer Res. 1999;59:2944–9.

    PubMed  CAS  Google Scholar 

  20. • Giles FJ, Vey N, Rizzieri D, et al. Phase I and pharmacokinetic study of elacytarabine, a novel 5’elaidic acid derivative of cytarabine, in adults with refractory hematologic malignancies. Leukemia. 2012;26:1686–9. Phase I testing of Elacytarabine in hematologic malignancies.

    Article  PubMed  CAS  Google Scholar 

  21. Giles F, O’Brien S, Cortes J, et al. Outcome of patients with acute myelogenous leukemia after second salvage therapy. Cancer. 2005;104:547–54.

    Article  PubMed  Google Scholar 

  22. Azuma A, Huang P, Matsuda A, et al. 2’-C-cyano-2’-deoxy-1-β-D-arabino-pentofuranosyl cytosine: a novel anticancer nuceloside analog that causes both DNA strand breaks and G2 arrest. Mol Pharmacol. 2001;59:725–31.

    PubMed  CAS  Google Scholar 

  23. Liu X, Wang Y, Benaissa S, et al. Homologous recombination as a resistance mechanism to replication-induced double-strand breaks caused by the anti-leukemia agent, CNDAC. Blood. 2010;116:1737–46.

    Article  PubMed  CAS  Google Scholar 

  24. Kantarjian H, Garcia-Manero G, O’Brien S, et al. Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome. J Clin Oncol. 2010;28:285–91.

    Article  PubMed  CAS  Google Scholar 

  25. • Kantarjian H, Faderl S, Garcia-Manero G, et al. Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomized phase 2 study. Lancet Oncol. 2012;13:1096–104. Phase II study of oral regimens of sapacitabine monotherapy in elderly AML.

    Article  PubMed  CAS  Google Scholar 

  26. Holowiecki J, Grosicki S, Robak T, et al. Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia: multicenter, phase III study. Leukemia. 2004;18:989–97.

    Article  PubMed  CAS  Google Scholar 

  27. • Holowiecki J, Grosicki S, Giebel S, et al. Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study. J Clin Oncol. 2012;30:2441–8. Phase III Study showing increased OS in young AML pts with addition of cladribine to “7 + 3” induction chemotherapy.

    Article  PubMed  CAS  Google Scholar 

  28. Hawtin RE, Stockett DE, Byl JA, et al. Voreloxin is an anticancer quinolone derivative that intercalates DNA and poisons topoisomerase II. PLoS One. 2010;5:e10186.

    Article  PubMed  Google Scholar 

  29. Advani RH, Hurwitz HI, Gordon MS, et al. Voreloxin, a first-in-class anticancer quinolone derivative, in relapsed/refractory solid tumors: a report on two dosing schedules. Clin Cancer Res. 2010;16:2167–75.

    Article  PubMed  CAS  Google Scholar 

  30. Lancet JE, Karp J, Cripe L, et al. Phase Ib/II pharmacokinetic/pharmacodynamic (PK/PD) study of combination voreloxin and cytarabine in relapsed or refractory AML patients [abstract 7005]. Presented at American Society of Clinical Oncology (ASCO) Annual Meeting. Orlando, Florida; May 29-June 2, 2009.

  31. Roboz GJ, Lancet JE, Cripe LD, et al. Final results of a phase II pharmacokinetic/pharmacodynamic (PK/PD) study of combination voreloxin and cytarabine in patients with relapsed or refractory acute myeloid leukemia [abstract 6526]. American Society of Clinical Oncology (ASCO) Annual Meeting. Chicago, IL; June 4–8, 2010.

  32. Stuart RK, Kashani FR, Cripe LD, et al.: Voreloxin single-agent treatment for older patients (60 years or older) with previously untreated acute myeloid leukemia: Final results from a phase II study with three schedules [abstract 6525]. American Society of Clinical Oncology (ASCO) Annual Meeting. Chicago, IL; June 4–8, 2010.

  33. Mehta C, Michelson G, Salganik M, et al. Adaptive design of VALOR, a phase III trial of vosaroxin or placebo in combination with cytarabine for patients with first relapsed or refractory acute myeloid leukemia [abstract TPS201]. American Society of Clinical Oncology (ASCO) Annual Meeting. Chicago, IL; June 3–7, 2011.

  34. Abbas JA, Stuart RK. Vosaroxin: a novel antineoplastic quinolone. Expert Opinions Investigational Drugs. 2012;21:1223–33.

    Article  CAS  Google Scholar 

  35. Feldman EJ, Lancet JE, Kolitz JE, et al. First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia. J Clin Oncol. 2011;29:979–85.

    Article  PubMed  CAS  Google Scholar 

  36. Tardi P, Johnstone S, Harasym N, et al. In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy. Leuk Res. 2009;33:129–39.

    Article  PubMed  CAS  Google Scholar 

  37. • Zediner JF, Gerber JM, Blackford A, et al. Randomized phase II trial of time-sequential therapy (TST) with flavopiridol (alvocidib), ara-c and mitoxantrone (FLAM) versus “7 + 3” for adults ages 70 years and under with newly diagnosed acute myeloid leukemia (AML). Blood (ASH Annual Meeting Abstracts). 2012;120:47. Ongoing study assessing FLAM vs “7 + 3” in younger AML patients with intermediate and high-risk features.

    Google Scholar 

  38. Karp JE, Blackford A, Smith BD, et al. Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone with adults with newly diagnosed poor risk acute myelogenous leukemia. Leuk Res. 2010;34:877–82.

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of Interest

Alice Mims declares that she has no conflict of interest.

Robert K. Stuart received grants from 430 Sunesis, Novartis, Coronado Biosciences, Millenium, Celtic Ther-431 apeutics, Spectrum Pharmaceuticals, Pfizer, Celator; Honoraria 432 from Sunesis, Moffitt Cancer Center, travel/accommodations: Sunesis

Author information

Authors and Affiliations

  1. Hollings Cancer Center, Medical University of South Carolina, 96 Jonathan Lucas Street, MSC 635 CSB 903, Charleston, SC, 29425, USA

    Alice Mims & Robert K. Stuart

Authors
  1. Alice Mims
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert K. Stuart
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert K. Stuart.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mims, A., Stuart, R.K. Developmental Therapeutics in Acute Myelogenous Leukemia: Are There Any New Effective Cytotoxic Chemotherapeutic Agents Out There?. Curr Hematol Malig Rep 8, 156–162 (2013). https://doi.org/10.1007/s11899-013-0158-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11899-013-0158-1

Keywords

Search

Navigation